XML 21 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 27, 2024
Dec. 29, 2023
Dec. 30, 2022
Cash flows from operating activities:      
Net income (loss) $ 22,570 $ 10,926 $ (8,448)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization 14,745 16,431 17,489
Other non-cash items (73) 1,445  
Deferred income taxes, net 2,615 2,582 (1,694)
(Gain) loss on sale/disposal of equipment (15) (63) (64)
Provision for doubtful accounts 740 825 243
Stock-based compensation 7,388 5,323 8,373
Accretion and fair value adjustments of contingent consideration 153   3,168
Changes in operating assets and liabilities, net of effects from business acquisitions:      
Accounts receivable 5,316 (10,300) 6,766
Contract assets 5,778 (10,825) (23,772)
Other receivables (1,133) 3,604 1,494
Prepaid expenses and other current assets (1,091) 2,566 (1,230)
Other assets 2,953 5,717 3,223
Accounts payable (831) 4,360 (7,839)
Accrued liabilities 4,707 5,030 12,970
Contract liabilities 8,373 598 (914)
Right-of-use assets (122) 995 (332)
Net cash (used in) provided by operating activities 72,073 39,214 9,433
Cash flows from investing activities:      
Purchase of equipment, software, and leasehold improvements (8,413) (9,925) (9,602)
Proceeds from sale of equipment 34 68 75
Cash paid for acquisitions, net of cash acquired (7,364) (1,600)  
Net cash (used in) provided by investing activities (15,743) (11,457) (9,527)
Cash flows from financing activities:      
Payments on contingent consideration   (4,000) (10,206)
Receipt of restricted cash     10,679
Payment on restricted cash   (10,679)  
Payments on notes payable (190) (1,631) (1,920)
Payments on debt issuance costs   (1,114) (177)
Proceeds from notes payable     1,718
Borrowings under term loan facility and line of credit   105,000 20,000
Repayments under term loan facility and line of credit (8,125) (112,875) (13,000)
Principal payments on finance leases (1,444) (1,304) (1,054)
Proceeds from stock option exercise 2,759 182 274
Proceeds from sales of common stock under employee stock purchase plan 2,838 2,781 3,036
Cash used to pay taxes on stock grants (1,407) (205) (992)
Net cash (used in) provided by financing activities (5,569) (23,845) 8,358
Net increase (decrease) in cash, cash equivalents and restricted cash 50,761 3,912 8,264
Cash, cash equivalents and restricted cash at beginning of period 23,397 19,485 11,221
Cash, cash equivalents and restricted cash at end of period 74,158 23,397 19,485
Cash paid (received) during the period for:      
Interest 7,520 10,193 5,066
Income taxes 1,316 (3,072) (1,120)
Supplemental disclosures of noncash investing and financing activities:      
Contingent consideration related to business acquisitions 4,060    
Equipment acquired under finance leases $ 1,605 $ 961 $ 2,451